Since MAPK signaling pathways may contribute to the pathogenesis of AD by regulation of neuronal apoptosis [62], phosphorylation of amyloid precursor protein (APP) and tau-protein [63], and other neuropsychiatric disorders, targeting MAPK pathways might offer new therapeutic approaches. The gene discussed is YWHAQ; the disease is Alzheimer disease.